VIVELLE
LOE ApproachingNDATRANSDERMALSYSTEM
Approved
Oct 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE is an estradiol transdermal system (patch) approved in 1994 for hormone replacement therapy in postmenopausal women. It delivers estradiol, the principal intracellular human estrogen, through the skin to replace declining endogenous estrogen levels. The drug works by binding to nuclear estrogen receptors to modulate symptoms of menopause and reduce elevated gonadotropin levels.
LOE Approaching
Brand faces erosion with moderate competitive pressure (30/100); reduced team investment likely as LOE approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIVELLE offers stability in a mature product but limited upside; roles focus on defending market share against generics and managing payer relationships. Career progression typically requires transition to growth-stage or launch products within the portfolio.
Brand ManagerField Sales Representative
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.